{
  "guideline": {
    "id": "PA166180000",
    "name": "Annotation of FDA Label for meclizine and CYP2D6",
    "source": "FDA",
    "version": 12,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166180000",
    "relatedChemicals": [
      {
        "id": "PA450338",
        "name": "meclizine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166309563",
      "name": "Recommendation Annotation PA166309563",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204002,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309565",
      "name": "Recommendation Annotation PA166309565",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204004,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"... when ANTIVERT® \\[meclizine\\] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.\" See label for more information."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309541",
      "name": "Recommendation Annotation PA166309541",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203980,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309567",
      "name": "Recommendation Annotation PA166309567",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204006,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309543",
      "name": "Recommendation Annotation PA166309543",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203982,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309569",
      "name": "Recommendation Annotation PA166309569",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204008,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309521",
      "name": "Recommendation Annotation PA166309521",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203960,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309481",
      "name": "Recommendation Annotation PA166309481",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203920,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309501",
      "name": "Recommendation Annotation PA166309501",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203940,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309571",
      "name": "Recommendation Annotation PA166309571",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204010,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309562",
      "name": "Recommendation Annotation PA166309562",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204001,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309564",
      "name": "Recommendation Annotation PA166309564",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204003,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309566",
      "name": "Recommendation Annotation PA166309566",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204005,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"... when ANTIVERT® \\[meclizine\\] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.\" See label for more information."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309542",
      "name": "Recommendation Annotation PA166309542",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203981,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309568",
      "name": "Recommendation Annotation PA166309568",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204007,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309544",
      "name": "Recommendation Annotation PA166309544",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203983,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309482",
      "name": "Recommendation Annotation PA166309482",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203921,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309570",
      "name": "Recommendation Annotation PA166309570",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204009,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309462",
      "name": "Recommendation Annotation PA166309462",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452203901,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309572",
      "name": "Recommendation Annotation PA166309572",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204011,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309561",
      "name": "Recommendation Annotation PA166309561",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450338",
          "name": "meclizine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452204000,
        "html": "<p>&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.\""
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product meclizine (NDA010721)",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010721"
    }
  ],
  "version": "2024-02-29-20-19"
}